- Aktieägarna i Karolinska Development AB (publ) kallas till årsstämma
- Notice of Annual General Meeting in Karolinska Development AB (publ)
- Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC
- Karolinska Developments portföljbolag Umecrine Cognition presenterar positiva säkerhetsdata från första delen av bolagets fas 1b/2-studie i PBC
- Karolinska Developments årsredovisning för 2023 har publicerats
- Karolinska Development Annual Report 2023 published
- Karolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million
- Karolinska Developments portföljbolag Aprea Therapeutics får IND-godkännande från FDA och säkrar finansiering om USD 34 miljoner
- Karolinska Developments portföljbolag Biosergen publicerar prospekt i samband med emission av units
- Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units
More ▼
Key statistics
On Wednesday, Karolinska Development AB (KDEV:STO) closed at 1.55, 9.93% above its 52-week low of 1.41, set on Oct 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.53 |
---|---|
High | 1.55 |
Low | 1.49 |
Bid | 1.55 |
Offer | 1.55 |
Previous close | 1.53 |
Average volume | 106.60k |
---|---|
Shares outstanding | 267.52m |
Free float | 94.80m |
P/E (TTM) | 76.65 |
Market cap | 409.31m SEK |
EPS (TTM) | 0.02 SEK |
Data delayed at least 15 minutes, as of Apr 24 2024 17:00 BST.
More ▼